Read this company snapshot
Daily valuation snapshot
CorMedix Inc.: source evidence dated 2026-10-09.
- Daily close (USD)
- $7.38
- Market capitalization (USD)
- $575,229,111.12
- Price / earnings (TTM)
- 3.07
- Price / book
- 1.25
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research CRMD in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research CRMD in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing CRMD with another company.
| Daily close (USD) | $7.38 |
| Market capitalization (USD) | $575,229,111.12 |
| Price / earnings (TTM) | 3.07 |
| Price / book | 1.25 |
No matching rows. Clear the filter to see all records.
Read CRMD's valuation metrics
Company size
CorMedix Inc.'s recorded market capitalization is $575,229,111.12. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
CRMD's recorded P/E is 3.07: about $3.07 of share price for each $1 of trailing annual earnings per share. Compare that multiple with earnings growth and companies in the same business.
Price relative to book equity
CRMD's recorded price-to-book ratio is 1.25. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research CorMedix Inc. with Aurora
Use the snapshot above to ask a specific question about CRMD. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow CRMD's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.